Targeted Cancer Therapy: Tyrosine Kinase Inhibitors

Author:

KÜPELİ Serhan1

Affiliation:

1. Cukurova University, Faculty of Medicine, Department of Pediatric Oncology and Pediatric Bone Marrow Transplantation Unit, Adana, Turkey

Abstract

Cancers generally contain multiple genetic and epigenetic abnormalities, but several key genes maintain the malignant phenotype and cellular survival. Tyrosine kinases are often involved in the cellular response with growth factors, cytokines, and hormones. These molecules are responsible for tumor growth by various mechanisms. It is thought that tyrosine kinase inhibitors may have a wide range of therapeutic efficacy. Significant response rates could not be obtained in phase 1 studies with any of the agents in monotherapy, and other options are being investigated by administering high doses in short periods and combining drugs that may affect different pathways.

Publisher

Archives Medical Review Journal

Subject

General Medicine

Reference19 articles.

1. 1. Maruyama IN. Mechanisms of activation of receptor tyrosine kinases: Monomers or dimers. Cell. 2014;3:304-330.

2. 2. Posner I, Engel M, Gazit A, Levitzki A. Kinetics of inhibition by tyrphostins of the tyrosine kinase activity of the epidermal growth factor receptor and analysis by a new computer program. Molecular Pharmacology. 1994;45:673-683.

3. 3.FDA Approved Drugs for Oncology. 2018. Available from: www.centerwatch.com/druginformation/fda-approved-drugs/therapeutic-area/12/oncology.

4. 4. Sequist LV. Second-generation epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. The Oncologist. 2007;12:325-330.

5. 5. Sillaber C, Mayerhofer M, Agis H, Sagaster V, Mannhalter C, Sperr WR et al. Chronic myeloid leukemia: Pathophysiology, diagnostic parameters, and current treatment concepts. Wiener Klinische Wochenschrift. 2003;115:485-504.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3